UPDATE: Morgan Stanley Upgrades Integra LifeSciences Holdings Following Acquisition of Confluent Surgical

In a report published Monday, Morgan Stanley analyst David R. Lewis upgraded the rating on Integra LifeSciences Holdings (NASDAQ: IART ) from Underweight to Equal-Weight, but removed the $40.00 price target. In the report, Morgan Stanley noted, “Integra's acquisition of Confluent Surgical business from Covidien is more accretive than the